Harpoon has developed a portfolio of novel T-cell engagers and proprietary platforms that deliver engineered proteins to direct a patient’s own immune cells to kill tumors. The company also has additional cancer drugs in early clinical trials, according to a Jan. 8 Merck news release.
The acquisition is expected to be completed in the first half of 2024.
Hospitals and clinics should plan to spend 11% to 13% more for prescription drugs in 2025 compared to last year,…
Boise, Idaho-based St. Luke’s Health System has erected automated medication lockers at supermarkets and other locations to increase access, ABC…
Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter…
Comments are closed.
